patricia: phase ii study of palbociclib, trastuzumab, and endocrine therapy in her2 advanced bc
Published 1 month ago • 49 plays • Length 0:44Download video MP4
Download video MP3
Similar videos
-
0:47
limitations and potential of phase ii patricia trial in her2 /hr advanced breast cancer
-
1:10
palbociclib, pembrolizumab, and endocrine therapy in hr /her2- breast cancer
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
1:43
composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer
-
1:49
phase ib data capitello-292: capivasertib palbociclib fulvestrant in hr /her2- breast cancer
-
1:12
results of a phase ii study of palbociclib in esophageal and gastric cancer
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
6:47
palbociclib: single-agent or in combination for the treatment of breast cancer
-
1:29
capitello-292: capivasertib, palbociclib, and fulvestrant for hr endocrine-resistant breast cancer
-
39:21
bcfnz webinar: palbociclib (ibrance) for advanced or metastatic hr breast cancer - nz update
-
7:09
palbociclib endocrine therapy vs capecitabine for hr-positive her2-negative breast cancer: pearl
-
8:25
paloma-1 study of palbociclib in er , her2-, breast cancer
-
2:21
palbociclib with adjuvant endocrine therapy in early breast cancer - pallas study
-
5:39
palmira clinical trial: evaluating efficacy and safety of palbociclib in advanced breast cancer
-
3:02
paloma-3: palbociclib plus fulvestrant in hormone receptor-positive advanced breast cancer
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
9:54
palbociclib endocrine therapy for hormone-positive her2-negative metastatic breast cancer: 5 cases
-
4:25
hormone receptor positive, her2- breast cancer clinical trial